Supporting MetMAb entry into the clinic with nonclinical pharmacokinetic (PK) and pharmacodynamic (PD) information

被引：2
|
作者：
Xiang, H. [1 ]
Reyes, A. [1 ]
Merchant, M. [2 ]
Bender, B. [3 ]
Jumbe, N. [3 ]
Young, J. [4 ]
Gelzleichter, T. [5 ]
Vaidyanathan, A. [5 ]
Peterson, A. [6 ]
Damico, L. [1 ]
机构：
[1] Genentech Inc, Early Dev PKPD, San Francisco, CA 94080 USA
[2] Genentech Inc, Canc Signaling & Translat Oncol, San Francisco, CA 94080 USA
[3] Genentech Inc, Clin PKPD, San Francisco, CA 94080 USA
[4] Genentech Inc, Assay & Automat Technol, San Francisco, CA 94080 USA
[5] Genentech Inc, Safety Assessment, San Francisco, CA 94080 USA
[6] Genentech Inc, Oncol Clin Sci ECD, San Francisco, CA 94080 USA
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(08)72462-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：167 / 167
页数：1
相关论文
共 50 条
  • [21] HYDROMORPHONE BIOAVAILABILITY AND PHARMACOKINETIC-PHARMACODYNAMIC (PK-PD) RELATIONSHIPS
    INTURRISI, C
    PORTENOY, R
    STILLMAN, M
    COLBURN, W
    FOLEY, K
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 43 (02) : 162 - 162
  • [22] In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis
    Xiao, Xia
    Sun, Jian
    Chen, Yi
    Huang, Rui-Juan
    Huang, Ting
    Qiao, Guilin Gary
    Zhou, Yu-Feng
    Liu, Ya-Hong
    BMC VETERINARY RESEARCH, 2015, 11
  • [23] Pharmacokinetic/pharmacodynamic (PK/PD) modeling of captopril in healthy volunteers.
    Yi, SY
    Bae, KS
    Lim, HS
    Cho, JY
    Yu, KS
    Jang, IJ
    Shin, SG
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (02) : P74 - P74
  • [24] METHADONE INFUSIONS - PHARMACOKINETIC-PHARMACODYNAMIC (PK-PD) RELATIONSHIPS
    INTURRISI, C
    PORTENOY, R
    MAX, M
    COLBURN, W
    FOLEY, K
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 41 (02) : 211 - 211
  • [25] Assessment of pharmacokinetic (PK) and pharmacodynamic (PD) interaction between warfarin and repaglinide
    Rosenberg, M
    Strange, P
    Cohen, A
    DIABETES, 1999, 48 : A356 - A356
  • [26] NONCLINICAL EFFICACY, PHARMACOKINETIC PROFILE AND PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) CORRELATION OF ALG-125755, A GALNAC-CONJUGATED siRNA, FOR FUNCTIONAL CURE OF CHRONIC HEPATITIS B
    Gupta, Kusum
    Fitzgerald, Megan E.
    Le, Kha
    Gohil, Vikrant
    Mukherjee, Sucheta
    Misner, Dinah
    Hong, Jin
    Kang, Hyunsoon
    Montero, Saul Martinez
    Rajwanshi, Vivek K.
    Lai, Felix
    Venkatraman, Meenakshi
    McClure, Matthew
    Chanda, Sushmita
    Fry, John
    Smith, David B.
    Symons, Julian A.
    Blatt, Lawrence M.
    Beigelman, Leonid N.
    Lin, Tse-I
    HEPATOLOGY, 2022, 76 : S276 - S277
  • [27] DEVELOPMENT OF A PHARMACOKINETIC (PK)/PHARMACODYNAMIC (PD) MODEL TO EVALUATE THE IMPACT OF PK VARIATION ON PD FOR EXTENDED RELEASE METOPROLOL FORMULATIONS
    Sharma, V. D.
    Trame, M. N.
    Schmidt, S.
    Fang, L. L.
    Lesko, L. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S9 - S9
  • [28] In vivo Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Establishment of the PK/PD Cutoff of Florfenicol Against Pasteurella multocida in Ducks
    Xiao, Xia
    Lan, Weixuan
    Zhao, Yaqin
    Li, Ruichao
    Liu, Yuan
    Liu, Juan
    Wang, Zhiqiang
    FRONTIERS IN MICROBIOLOGY, 2021, 11
  • [29] PRACTICAL IMPLICATIONS OF PHARMACOKINETIC AND PHARMACODYNAMIC (PK/PD) MODELING OF DRUG DOSE REGIMENS
    BAGGOT, JD
    EQUINE VETERINARY JOURNAL, 1995, 27 (04) : 245 - 246
  • [30] Population pharmacokinetic (PK)-pharmacodynamic (PD) model for gefitinib in cancer patients.
    Li, J
    Karlsson, MO
    Brahmer, J
    Cusatis, G
    Hidalgo, M
    Baker, SD
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 212S - 212S
12345